Table 2.
Surgical treatment and postoperative antimicrobial regimen in 60 patients with Propionibacterium-associated PJI, presented according to their postoperative antimicrobial treatment
| Characteristic | Rifampicin (n = 39) |
No rifampicin (n = 21) |
Total group (n = 60) |
p-value |
|---|---|---|---|---|
| Surgical treatment | 0.5 | |||
| Debridement and prosthesis retention | 5 | 1 | 6 | |
| 1-stage revision (partial revision) | 25 (5) | 16 (5) | 41 (10) | |
| 2-stage revision | 9 | 4 | 13 | |
| Antibiotic treatment (daily doses) | ||||
| Clindamycin 600 mg x 3 and rifampicin 450 mg x 2 | 33 | – | 33 | |
| Teicoplanin 400 mg x 1 i.v. and rifampicin 450 mg x 2 | 6 | – | 6 | |
| Clindamycin 600 mg x 3 | – | 16 | 16 | |
| Amoxicillin 500 mg x 4 | – | 1 | 1 | |
| Ciprofloxacin 750 mg x 2 and clindamycin 600 mg x 3 | – | 1 | 1 | |
| Doxycycline 200 mg x 1 | – | 1 | 1 | |
| Linezolid 600 mg x 2 | – | 1 | 1 | |
| Teicoplanin 400 mg x 1 i.v. | – | 1 | 1 |
i.v.: intravenously.